These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33567475)

  • 1. A novel estimand to adjust for rescue treatment in randomized clinical trials.
    Michiels H; Sotto C; Vandebosch A; Vansteelandt S
    Stat Med; 2021 Apr; 40(9):2257-2271. PubMed ID: 33567475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using modified intention-to-treat as a principal stratum estimator for failure to initiate treatment.
    Kahan BC; White IR; Edwards M; Harhay MO
    Clin Trials; 2023 Jun; 20(3):269-275. PubMed ID: 36916466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of estimand and analysis methods in diabetes trials with rescue medication.
    Holzhauer B; Akacha M; Bermann G
    Pharm Stat; 2015; 14(6):433-47. PubMed ID: 26337856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A causal modelling framework for reference-based imputation and tipping point analysis in clinical trials with quantitative outcome.
    White IR; Joseph R; Best N
    J Biopharm Stat; 2020 Mar; 30(2):334-350. PubMed ID: 31718423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the Estimand Framework to Anesthesia Trials.
    De Silva AP; Leslie K; Braat S; Grobler AC
    Anesthesiology; 2024 Jul; 141(1):13-23. PubMed ID: 38743905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION.
    Bao W; Gaffney M; Pressler ML; Fayyad R; Wisemandle W; Beckerman B; Wolski KE; Nissen SE
    Clin Trials; 2020 Oct; 17(5):535-544. PubMed ID: 32643966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation.
    White IR; Bamias C; Hardy P; Pocock S; Warner J
    Stat Med; 2001 Oct; 20(20):2995-3008. PubMed ID: 11590628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating questions to estimands in randomized clinical trials with intercurrent events.
    Stensrud MJ; Dukes O
    Stat Med; 2022 Jul; 41(16):3211-3228. PubMed ID: 35578779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating Treatment Effects for Recurrent Events in the Presence of Rescue Medications: An Application to the Immune Thrombocytopenia Study.
    Gao F; Zeng D; Wei H; Wang X; Ibrahim JG
    Stat Biosci; 2018 Aug; 10(2):473-489. PubMed ID: 30298095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient, doubly robust estimation of the effect of dose switching for switchers in a randomized clinical trial.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Biom J; 2021 Oct; 63(7):1464-1475. PubMed ID: 34247409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining estimands using a mix of strategies to handle intercurrent events in clinical trials.
    Qu Y; Shurzinske L; Sethuraman S
    Pharm Stat; 2021 Mar; 20(2):314-323. PubMed ID: 33098267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Power and sample sizes estimation in clinical trials with treatment switching in intention-to-treat analysis: a simulation study.
    Deng L; Hsu CY; Shyr Y
    BMC Med Res Methodol; 2023 Feb; 23(1):49. PubMed ID: 36823545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The attributable estimand: A new approach to account for intercurrent events.
    Darken P; Nyberg J; Ballal S; Wright D
    Pharm Stat; 2020 Sep; 19(5):626-635. PubMed ID: 32198954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimands-A Basic Element for Clinical Trials.
    Pohl M; Baumann L; Behnisch R; Kirchner M; Krisam J; Sander A
    Dtsch Arztebl Int; 2021 Dec; 118(51-52):883-888. PubMed ID: 34857075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intention-to-treat analysis with treatment discontinuation and missing data in clinical trials.
    Little R; Kang S
    Stat Med; 2015 Jul; 34(16):2381-90. PubMed ID: 25363683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events.
    Lou Y; Jones MP; Sun W
    Stat Med; 2019 Nov; 38(27):5214-5235. PubMed ID: 31621943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simple Estimation of Patient-Oriented Effects From Randomized Trials: An Open and Shut CACE.
    Steele RJ; Shrier I; Kaufman JS; Platt RW
    Am J Epidemiol; 2015 Sep; 182(6):557-66. PubMed ID: 26283090
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.